Placebo to MK-1242 tablet 2.5 and 5 mg clinical trials

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

This study looks at a new drug, vericiguat, for people with long-term heart failure where the heart struggles to pump blood. It compares vericiguat with a dummy pill to see if it can prevent heart-related deaths or hospital stays, and if it's safe.